Therapeutic potential of targeting cathepsin S in pulmonary fibrosis

Cathepsin S (CTSS), a lysosomal protease, belongs to a family of cysteine cathepsin proteases that promote degradation of damaged proteins in the endolysosomal pathway. Aberrant CTSS expression and regulation are associated with the pathogenesis of several diseases, including lung diseases. CTSS ove...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	YoungJo Yoo, Eun Choi, Yejin Kim, Yunyoung Cha, Eunhye Um, Younghwa Kim, Yunji Kim, Yun-Sil Lee
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2022
Materias:	Cathepsin S Pulmonary fibrosis Therapeutic target Inhibitors Clinical and preclinical Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/b449d7c5e2074c2aa98e91e2e9c3c139
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b449d7c5e2074c2aa98e91e2e9c3c139
record_format	dspace
spelling	oai:doaj.org-article:b449d7c5e2074c2aa98e91e2e9c3c1392021-12-04T04:33:04ZTherapeutic potential of targeting cathepsin S in pulmonary fibrosis0753-332210.1016/j.biopha.2021.112245https://doaj.org/article/b449d7c5e2074c2aa98e91e2e9c3c1392022-01-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S0753332221010295https://doaj.org/toc/0753-3322Cathepsin S (CTSS), a lysosomal protease, belongs to a family of cysteine cathepsin proteases that promote degradation of damaged proteins in the endolysosomal pathway. Aberrant CTSS expression and regulation are associated with the pathogenesis of several diseases, including lung diseases. CTSS overexpression causes a variety of pathological processes, including pulmonary fibrosis, with increased CTSS secretion and accelerated extracellular matrix remodeling. Compared to many other cysteine cathepsin family members, CTSS has unique features that it presents limited tissue expression and retains its enzymatic activity at a neutral pH, suggesting its decisive involvement in disease microenvironments. In this review, we investigated the role of CTSS in lung disease, exploring recent studies that have indicated that CTSS mediates fibrosis in unique ways, along with its structure, substrates, and distinct regulation. We also outlined examples of CTSS inhibitors in clinical and preclinical development and proposed CTSS as a potential therapeutic target for pulmonary fibrosis.YoungJo YooEun ChoiYejin KimYunyoung ChaEunhye UmYounghwa KimYunji KimYun-Sil LeeElsevierarticleCathepsin SPulmonary fibrosisTherapeutic targetInhibitorsClinical and preclinicalTherapeutics. PharmacologyRM1-950ENBiomedicine & Pharmacotherapy, Vol 145, Iss , Pp 112245- (2022)
institution	DOAJ
collection	DOAJ
language	EN
topic	Cathepsin S Pulmonary fibrosis Therapeutic target Inhibitors Clinical and preclinical Therapeutics. Pharmacology RM1-950
spellingShingle	Cathepsin S Pulmonary fibrosis Therapeutic target Inhibitors Clinical and preclinical Therapeutics. Pharmacology RM1-950 YoungJo Yoo Eun Choi Yejin Kim Yunyoung Cha Eunhye Um Younghwa Kim Yunji Kim Yun-Sil Lee Therapeutic potential of targeting cathepsin S in pulmonary fibrosis
description	Cathepsin S (CTSS), a lysosomal protease, belongs to a family of cysteine cathepsin proteases that promote degradation of damaged proteins in the endolysosomal pathway. Aberrant CTSS expression and regulation are associated with the pathogenesis of several diseases, including lung diseases. CTSS overexpression causes a variety of pathological processes, including pulmonary fibrosis, with increased CTSS secretion and accelerated extracellular matrix remodeling. Compared to many other cysteine cathepsin family members, CTSS has unique features that it presents limited tissue expression and retains its enzymatic activity at a neutral pH, suggesting its decisive involvement in disease microenvironments. In this review, we investigated the role of CTSS in lung disease, exploring recent studies that have indicated that CTSS mediates fibrosis in unique ways, along with its structure, substrates, and distinct regulation. We also outlined examples of CTSS inhibitors in clinical and preclinical development and proposed CTSS as a potential therapeutic target for pulmonary fibrosis.
format	article
author	YoungJo Yoo Eun Choi Yejin Kim Yunyoung Cha Eunhye Um Younghwa Kim Yunji Kim Yun-Sil Lee
author_facet	YoungJo Yoo Eun Choi Yejin Kim Yunyoung Cha Eunhye Um Younghwa Kim Yunji Kim Yun-Sil Lee
author_sort	YoungJo Yoo
title	Therapeutic potential of targeting cathepsin S in pulmonary fibrosis
title_short	Therapeutic potential of targeting cathepsin S in pulmonary fibrosis
title_full	Therapeutic potential of targeting cathepsin S in pulmonary fibrosis
title_fullStr	Therapeutic potential of targeting cathepsin S in pulmonary fibrosis
title_full_unstemmed	Therapeutic potential of targeting cathepsin S in pulmonary fibrosis
title_sort	therapeutic potential of targeting cathepsin s in pulmonary fibrosis
publisher	Elsevier
publishDate	2022
url	https://doaj.org/article/b449d7c5e2074c2aa98e91e2e9c3c139
work_keys_str_mv	AT youngjoyoo therapeuticpotentialoftargetingcathepsinsinpulmonaryfibrosis AT eunchoi therapeuticpotentialoftargetingcathepsinsinpulmonaryfibrosis AT yejinkim therapeuticpotentialoftargetingcathepsinsinpulmonaryfibrosis AT yunyoungcha therapeuticpotentialoftargetingcathepsinsinpulmonaryfibrosis AT eunhyeum therapeuticpotentialoftargetingcathepsinsinpulmonaryfibrosis AT younghwakim therapeuticpotentialoftargetingcathepsinsinpulmonaryfibrosis AT yunjikim therapeuticpotentialoftargetingcathepsinsinpulmonaryfibrosis AT yunsillee therapeuticpotentialoftargetingcathepsinsinpulmonaryfibrosis
_version_	1718373050807746560

Therapeutic potential of targeting cathepsin S in pulmonary fibrosis

Ejemplares similares